Ektomun® is derived from the validated Triomab® platform of which the most advanced candidate reached the market in 2009.

undefinedLearn more about TRION Pharma's Triomab® platform

LINDIS Biotech was founded to develop ektomun®, an innovative immunotherapeutic for the treatment of small cell lung cancer, melanoma and other neuroectodermal cancers that currently lack sufficient treatment options.

The company is managed by Horst Lindhofer, inventor of the underlying trifunctional antibody technology and CEO of TRION Pharma.